Biotech Values

[mcbio]

T-DM1 showed statsig PFS in the same phase-2 study:

finance.yahoo.com/news/TDM1-Significantly-Improved-bw-3677346054.html?x=0&.v=1

I like IMGN but I think it's crazy that the stock jumped ~27% on this news. While I realize they are saving the details for a future medical conference, this PR today doesn't tell us much. So T-DM1 "had a significant improvement in progression-free survival compared with patients treated with Herceptin® (trastuzumab) plus chemotherapy (docetaxel)." So what exactly is "significant"? And who knows if such improvement was stat sig. And will this PFS improvement be able to translate into an OS benefit? Lot of questions to still be answered for a ~27% jump in share price.